Navigation Links
VEGF Neutralization Can Damage Brain Vessels, Say Schepens Eye Research Institute Scientists

Could have impact on cancer treatment and other systemic uses of drugs to

target vascular endothelial growth factor (VEGF)

BOSTON, Feb. 13 /PRNewswire/ -- New research by scientists at Schepens Eye Research Institute may help explain why the anti-cancer drug Avastin, which targets a growth factor responsible for creation of new blood vessels, causes potentially fatal brain inflammation in certain patients. Institute scientists mimicked the drug's activity in mice and found that it damaged the cell lining that prevents fluid from leaking from the ventricle into the brain. The ventricle is the structure in the brain that holds cerebral spinal fluid after it is produced and which is continuous with the spinal cord. The results are currently published online (on February 11th) in The Journal of Experimental Medicine.

"This finding is significant because it may ultimately modify the way we use systemic drugs that block blood vessel growth, and it also suggests that VEGF (vascular endothelial growth factor) plays a more extensive role in the body than we previously thought," says Dr. Patricia D'Amore, senior scientist at Schepens Eye Research Institute and principal investigator of the study.

The cancer drug Avastin (bevacizumab) is used to treat advanced bowel cancer in combination with chemotherapy. By targeting VEGF, Avastin inhibits the growth of tumors by cutting off their blood supply and thus depriving them of oxygen and other nutrients. In a small percentage of patients, however, Avastin can cause neurological side effects, ranging from headaches and blurry vision to potentially fatal seizures and brain swelling.

D'Amore and her team found that VEGF normally protects the specialized cells that create a seal between the brain and ventricle and thus prevent fluid from leaking into the brain. When VEGF was blocked in mice, these cells were damaged and the animals developed brain lesions. The authors suspect that Avastin's side effects in humans may be caused by a similar phenomenon. Why these symptoms occur in only a few patients is not yet known.

Authors of the study include: Arindel S.R. Maharaj(2,3), Tony E. Walshe(2,3), Magali Saint-Geniez(2,3), Shivalingappa Venkatesha(2,4), Angel E. Maldonado (2,3), Nathan C. Himes(2), Kabir S. Matharu(3), S. Ananth Karumanchi(2,4) and Patricia A. D'Amore(1,2,3)

(1) Departments of Ophthalmology and Pathology

(2) Harvard Medical School

(3) Schepens Eye Research Institute

(4) Center for Vascular Biology, Departments of Medicine, Obstetrics,

Gynecology, Surgery and Pathology, Beth Israel

Deaconess Medical Center.

Schepens Eye Research Institute is an affiliate of Harvard Medical School and the largest independent eye research institute in the nation.

SOURCE Schepens Eye Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VEGF neutralization can damage brain vessels, say Schepens Eye Research Institute scientists
2. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
3. Anti-cancer drug damages brain vessels
4. Novel compound may lessen heart attack damage
5. Gene predicts heart attack response and cardiac damage
6. Regular marijuana use increases risk of hepatitis C-related liver damage
7. Over-the-counter eardrops may cause hearing loss or damage
8. Over-the-counter eardrops may cause hearing loss or damage
9. Evolution of human genomes guardian gives people unique protections from DNA damage
10. Priming Heart Before an Attack Could Limit Damage
11. Genes identified that protect against heart damage from chemotherapy
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), ... population health arenas, is pleased to announce that VIP Care Services, a Caprock ... implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case management ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 During ... in San Francisco, CA , ... to the coronary marketplace. During a satellite symposium, ... Stent Design to Minimize Restenosis", a renowned physician ... available Medinol NIRxcell™ CoCr Coronary Stent System and ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... addition of the "Veterinary Equipment and Disposables ... to 2020" report to their offering. ... of the "Veterinary Equipment and Disposables Market ... 2020" report to their offering. --> ...
(Date:12/1/2015)... , Dec. 1, 2015   MabVax Therapeutics Holdings, ... company, announces it has filed an Investigational New Drug ... (FDA) for the Company,s lead fully human antibody product ... acceptance, MabVax plans to initiate the Phase I clinical ... --> The planned Phase I trial ...
Breaking Medicine Technology: